QURE vs. CNTA
QURE (uniQure N.V.) and CNTA (Centessa Pharmaceuticals Limited) are both stocks. Both operate in the Biotechnology industry within the Healthcare sector. Over the past 5 years, QURE returned -5.87%/yr vs 12.71%/yr for CNTA. At a 0.24 correlation, their price movements are largely independent.
Performance
QURE vs. CNTA - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, QURE achieves a 12.83% return, which is significantly lower than CNTA's 58.74% return.
QURE
- 1D
- 2.08%
- 1M
- -2.39%
- YTD
- 12.83%
- 6M
- 24.02%
- 1Y
- 56.34%
- 3Y*
- 11.25%
- 5Y*
- -5.87%
- 10Y*
- 8.62%
CNTA
- 1D
- 0.20%
- 1M
- 0.28%
- YTD
- 58.74%
- 6M
- 34.58%
- 1Y
- 233.05%
- 3Y*
- 104.97%
- 5Y*
- 12.71%
- 10Y*
- —
QURE vs. CNTA - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
QURE uniQure N.V. | 12.83% | 35.50% | 160.86% | -70.14% | 9.31% | -40.28% |
CNTA Centessa Pharmaceuticals Limited | 58.74% | 49.31% | 110.43% | 156.77% | -72.47% | -48.23% |
Correlation
The correlation between QURE and CNTA is 0.16, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.16 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.23 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.25 |
Correlation (All Time) Calculated using the full available price history since Jun 1, 2021 | 0.24 |
Fundamentals
QURE:
-$3.58
CNTA:
-$1.81
QURE:
87.14
CNTA:
354.44
QURE:
$18.09M
CNTA:
$15.00M
QURE:
$13.42M
CNTA:
$15.00M
QURE:
-$164.53M
CNTA:
-$227.27M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
QURE vs. CNTA — Risk / Return Rank
QURE
CNTA
QURE vs. CNTA - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for uniQure N.V. (QURE) and Centessa Pharmaceuticals Limited (CNTA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| QURE | CNTA | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -3.33 | ||
| Sortino ratioReturn per unit of downside risk | -2.47 | ||
| Omega ratioGain probability vs. loss probability | 1.43 | 1.69 | -0.27 |
| Calmar ratioReturn relative to maximum drawdown | 0.65 | 8.90 | -8.25 |
| Martin ratioReturn relative to average drawdown | 1.06 | 24.63 | -23.57 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading charts...
Sharpe Ratios by Period
| QURE | CNTA | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | 0.21 | 3.54 | -3.33 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | -0.04 | 0.18 | -0.22 |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | 0.07 | — | — |
Sharpe Ratio (All Time)Calculated using the full available price history | 0.05 | 0.18 | -0.13 |
Drawdowns
QURE vs. CNTA - Drawdown Comparison
The maximum QURE drawdown since its inception was -95.40%, which is greater than CNTA's maximum drawdown of -88.19%. Use the drawdown chart below to compare losses from any high point for QURE and CNTA.
Loading charts...
Drawdown Indicators
| QURE | CNTA | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -95.40% | -88.19% | -7.21% |
Max Drawdown (1Y)Largest decline over 1 year | -87.21% | -26.38% | -60.83% |
Max Drawdown (3Y)Largest decline over 3 years | -87.21% | -43.72% | -43.49% |
Max Drawdown (5Y)Largest decline over 5 years | -90.11% | -88.19% | -1.92% |
Max Drawdown (10Y)Largest decline over 10 years | -95.40% | — | — |
Current DrawdownCurrent decline from peak | -67.15% | -0.50% | -66.65% |
Average DrawdownAverage peak-to-trough decline | -56.58% | -51.99% | -4.59% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 53.50% | 9.51% | +43.99% |
Volatility
QURE vs. CNTA - Volatility Comparison
uniQure N.V. (QURE) has a higher volatility of 28.01% compared to Centessa Pharmaceuticals Limited (CNTA) at 0.72%. This indicates that QURE's price experiences larger fluctuations and is considered to be riskier than CNTA based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| QURE | CNTA | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 28.01% | 0.72% | +27.29% |
Volatility (6M)Calculated over the trailing 6-month period | 92.44% | 44.27% | +48.17% |
Volatility (1Y)Calculated over the trailing 1-year period | 273.61% | 66.48% | +207.13% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 154.08% | 72.09% | +81.99% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 119.92% | 72.30% | +47.62% |
Dividends
QURE vs. CNTA - Dividend Comparison
Neither QURE nor CNTA has paid dividends to shareholders.
Financials
QURE vs. CNTA - Financials Comparison
This section allows you to compare key financial metrics between uniQure N.V. and Centessa Pharmaceuticals Limited. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
Frequently Asked Questions
QURE and CNTA have a correlation of 0.16, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
QURE has higher volatility (28.01%) compared to CNTA (0.72%). In terms of maximum drawdown, QURE dropped -95.40% vs CNTA's -88.19%.
CNTA currently has the higher Sharpe Ratio (3.54 vs 0.21), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for QURE and CNTA
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer